摘要
大腸及直腸的神經內分泌腫瘤雖然相較於大腸直腸腺癌，發生率較低，但隨著大腸鏡的普及，發生率近年來有上升的趨勢。關於神經內分泌腫瘤相關的研究，多著墨於肺臟及胰臟這兩個器官，故此篇會詳述有關大腸直腸內分泌腫瘤的流行病學、臨床表現、病理型態、免疫染色、分級及分期、分子病理、治療及預後等的相關進展。
參考文獻
3. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
4. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53.
5. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
6. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18.
7. Sabha N, Knobbe CB, Maganti M, et al. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol 2014;16:914-23.
延伸閱讀
- Yang, P. H., Huang, C. W., Tsai, H. L., Su, W. C., Chang, T. K., Chen, P. J., Chen, Y. C., Wu, C. T., Liang, P. I., & Wang, J. (2022). 盲腸大細胞神經內分泌惡性腫瘤：病例報告及文獻回顧. 南臺灣醫學雜誌, 18(2), 65-72. https://doi.org/10.6726/MJST.202212_18(2).0003
- Hsu, W. H., Wu, I. C., Chen, C. Y., Liu, C. S., Chen, H. W., & Wu, D. C. (2009). 大腸神經鞘瘤：病例報告. 內科學誌, 20(3), 255-259. https://doi.org/10.6314/JIMT.2009.20(3).09
- Lai, S. L., Hung, J. S., Huang, J., Lin, B. R., & Liang, J. T. (2016). 大腸直腸神經內分泌瘤之治療與預後. 中華民國大腸直腸外科醫學會雜誌, 27(3), 91-99. https://doi.org/10.6312/SCRSTW.2016.27(3).10424
- 楊絡勝、梁金銅（2017）。大腸直腸神經內分泌瘤的病例報告與治療成果。臺灣醫界，60(3)，8-12。https://www.airitilibrary.com/Article/Detail?DocID=17263603-201703-201704180009-201704180009-8-12
- Chang, T. C., Liang, J. T., Lin, B. R., & Huang, J. (2009). 直腸的胃腸間質腫瘤在腫瘤外科之治療成果. 中華民國大腸直腸外科醫學會雜誌, 20(4), 87-93. https://doi.org/10.6312/SCRSTW.2009.20(4).09811